Your browser doesn't support javascript.
loading
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Kaneko, Yutaro; Hatano, Ryo; Hirota, Naoto; Isambert, Nicolas; Trillet-Lenoir, Véronique; You, Benoit; Alexandre, Jérôme; Zalcman, Gérard; Valleix, Fanny; Podoll, Thomas; Umezawa, Yoshimi; Takao, Seiichi; Iwata, Satoshi; Hosono, Osamu; Taguchi, Tetsuo; Yamada, Taketo; Dang, Nam H; Ohnuma, Kei; Angevin, Eric; Morimoto, Chikao.
Afiliación
  • Kaneko Y; Y's AC Co., Ltd., 2-6-8, Kudan-minami, Chiyoda-ku, Tokyo, 102-0074, Japan. y.kaneko@ys-ac.com.
  • Hatano R; Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Hirota N; Stella Co., Ltd., Tokyo, Japan.
  • Isambert N; Centre Georges-François Leclerc, Unité de Phases Précoces, Dijon, France.
  • Trillet-Lenoir V; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France.
  • You B; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France.
  • Alexandre J; Hôpital Cochin, Paris, France.
  • Zalcman G; Centre Hospitalier Universitaire (CHU) de Caen, Centre de Recherche Clinique/Essais de phases précoces, Caen, France.
  • Valleix F; FV Clinical subcontractor for SynteractHCR SAS, Levallois-Perret, France.
  • Podoll T; Y's therapeutics Inc., Redwood City, CA, USA.
  • Umezawa Y; Stella Co., Ltd., Tokyo, Japan.
  • Takao S; Stella Co., Ltd., Tokyo, Japan.
  • Iwata S; Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Hosono O; Department of Rheumatology and Allergy, IMSUT Hospital, The University of Tokyo, Tokyo, Japan.
  • Taguchi T; Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Yamada T; Saitama Medical University, Saitama, Japan.
  • Dang NH; Keio University School of Medicine, Tokyo, Japan.
  • Ohnuma K; Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA.
  • Angevin E; Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Morimoto C; Gustave Roussy, Drug Development Department (DITEP), Université Paris-Saclay, Villejuif, France.
Biomark Res ; 9(1): 21, 2021 Mar 23.
Article en En | MEDLINE | ID: mdl-33757558
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies Idioma: En Revista: Biomark Res Año: 2021 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies Idioma: En Revista: Biomark Res Año: 2021 Tipo del documento: Article País de afiliación: Japón